XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib

June 2, 2026 — Karyopharm Therapeutics Inc. announced its late-breaking abstract was accepted for an oral presentation at the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). The presentation covers the Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled study evaluating once-weekly 60 mg selinexor plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor–naïve myelofibrosis (N=353; 2:1 randomization; platelets >100×10^9/L), with co-primary endpoints of SVR35 at week 24 and symptom score change over 24 weeks.

Karyopharm highlights data indicating the combination produced rapid, deep, and sustained spleen volume reductions, similar symptom improvement, a “promising” overall survival signal, and more patients achieving ≥20% variant allele frequency reductions as early as week 24, with manageable safety.

New data include a post-hoc analysis of 24 patients from the Phase 1 portion suggesting achievement of SVR35 may predict overall survival, consistent with a similar Phase 3 analysis. The abstract (LB5002) was selected as one of six top late-breaking oral presentations.